ro.co glp-1 Ro Launches Insurance Coverage Checker Wondering how GLP-1s actually work?

The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide) has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and fatal pancreatitis

A public health expert explains how GLP-1 drugs have changed the way healthcare providers understand and treat obesity.

High-Potency Formula Provides Akkermansia muciniphila plus chicory inulin for targeted microbiome support

Background Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety